NASDAQ:ADXN Addex Therapeutics (ADXN) Stock Price, News & Analysis → Has Jeff Bezos Found the Next Nvidia? (From InvestorPlace) (Ad) Free ADXN Stock Alerts Notice: Trading of Addex Therapeutics halted at 10:01 AM EST due to "LULD pause". $7.54 -8.56 (-53.17%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$7.50▼$9.2150-Day Range$7.54▼$27.9052-Week Range$5.00▼$27.90Volume160,385 shsAverage Volume18,570 shsMarket Capitalization$7.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Addex Therapeutics alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Addex Therapeutics Stock (NASDAQ:ADXN)Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Read More ADXN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADXN Stock News HeadlinesApril 29, 2024 | msn.comTech Rally Subsides as US Equity Futures Waver Pre-BellApril 29, 2024 | msn.comAddex stock plunges 50% on failed study for epilepsy drugApril 29, 2024 | InvestorPlace (Ad)Has Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…April 29, 2024 | finanznachrichten.deAddex Therapeutics: Addex Provides Update on ADX71149 Phase 2 Epilepsy StudyApril 29, 2024 | globenewswire.comAddex Provides Update on ADX71149 Phase 2 Epilepsy StudyApril 26, 2024 | americanbankingnews.comShort Interest in Addex Therapeutics Ltd (NASDAQ:ADXN) Increases By 149.4%April 19, 2024 | globenewswire.comAddex to Present at the Swiss Biotech Day 2024April 18, 2024 | investorplace.comADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023April 29, 2024 | InvestorPlace (Ad)Has Jeff Bezos Found the Next Nvidia?If you’ve sat back and watched companies like Nvidia and AMD soar over 2,000% over the past several years… And wondered what was next… This is a fast-moving story, but if you want the chance to profit alongside Jeff Bezos in the next big tech trend, go ahead and…April 18, 2024 | seekingalpha.comAddex Therapeutics GAAP EPS of -CHF 0.14, revenue of CHF 1.65MApril 18, 2024 | globenewswire.comAddex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateApril 11, 2024 | globenewswire.comAddex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024April 3, 2024 | finanznachrichten.deNeurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological DisordersApril 3, 2024 | markets.businessinsider.comAddex Announces Launch Of Neurosterix In Partnership With Perceptive - Quick FactsApril 3, 2024 | globenewswire.comAddex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological DisordersMarch 14, 2024 | globenewswire.comAddex to Present at the Bio-Europe Spring 2024 ConferenceFebruary 22, 2024 | benzinga.comAddex Therapeutics Stock (NASDAQ:ADXN), Short Interest ReportJanuary 31, 2024 | finance.yahoo.comAddex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.January 9, 2024 | finance.yahoo.comAddex to Present at the Swiss Equities Baader ConferenceJanuary 5, 2024 | finance.yahoo.comAddex to Present at Biotech Showcase™ 2024December 23, 2023 | thestreet.comAddex Therapeutics LtdDecember 20, 2023 | finanznachrichten.deAddex Therapeutics: Addex Shareholders Approve All Resolutions at Extraordinary General MeetingDecember 20, 2023 | finance.yahoo.comAddex Shareholders Approve All Resolutions at Extraordinary General MeetingDecember 14, 2023 | finance.yahoo.comAddex Creates Treasury SharesNovember 29, 2023 | msn.comAddex Therapeutics GAAP EPS of -CHF0.03, income of CHF0.33MNovember 29, 2023 | markets.businessinsider.comAddex Therapeutics Posts Narrower Loss In Q3 - Quick FactsNovember 29, 2023 | finance.yahoo.comAddex Reports Q3 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADXN CUSIPN/A CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($18.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,760,000.00 Net Margins-644.66% Pretax Margin-654.37% Return on Equity-277.56% Return on Assets-156.81% Debt Debt-to-Equity RatioN/A Current Ratio1.46 Quick Ratio1.46 Sales & Book Value Annual Sales$1.83 million Price / Sales4.37 Cash FlowN/A Price / Cash FlowN/A Book Value$1.20 per share Price / Book6.28Miscellaneous Outstanding Shares1,060,000Free Float901,000Market Cap$7.99 million OptionableNot Optionable Beta1.66 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Timothy Mark Dyer (Age 56)Co-Founder, CEO & Director Dr. Roger G. Mills M.D. (Age 67)Chief Medical Officer & Director Mr. Lénaic Teyssédou (Age 38)Head of Finance Dr. Mikhail Kalinichev Ph.D. (Age 57)Head of Translational Science Key CompetitorsAptorum GroupNASDAQ:APMBioVieNASDAQ:BIVIRenovoRxNASDAQ:RNXTVincerx PharmaNASDAQ:VINCAlaunos TherapeuticsNASDAQ:TCRTView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 494,000 shares on 2/13/2024Ownership: 4.343%View All Institutional Transactions ADXN Stock Analysis - Frequently Asked Questions Should I buy or sell Addex Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares. View ADXN analyst ratings or view top-rated stocks. How have ADXN shares performed in 2024? Addex Therapeutics' stock was trading at $6.05 at the beginning of the year. Since then, ADXN stock has increased by 24.6% and is now trading at $7.54. View the best growth stocks for 2024 here. Are investors shorting Addex Therapeutics? Addex Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 21,700 shares, an increase of 149.4% from the March 31st total of 8,700 shares. Based on an average daily volume of 17,100 shares, the days-to-cover ratio is presently 1.3 days. Currently, 2.7% of the shares of the company are sold short. View Addex Therapeutics' Short Interest. When is Addex Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ADXN earnings forecast. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd (NASDAQ:ADXN) issued its earnings results on Thursday, November, 4th. The company reported ($14.40) EPS for the quarter, meeting the consensus estimate of ($14.40). The business earned $0.83 million during the quarter, compared to the consensus estimate of $0.42 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 277.56% and a negative net margin of 644.66%. During the same quarter last year, the business posted ($15.60) EPS. When did Addex Therapeutics' stock split? Addex Therapeutics shares reverse split on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADXN) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI stock to buy right nowStockEarningsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
